122 related articles for article (PubMed ID: 22146763)
1. Role of circulating free alu DNA in endometrial cancer.
Tanaka H; Tsuda H; Nishimura S; Nomura H; Kataoka F; Chiyoda T; Tanaka K; Iguchi Y; Susumu N; Aoki D
Int J Gynecol Cancer; 2012 Jan; 22(1):82-6. PubMed ID: 22146763
[TBL] [Abstract][Full Text] [Related]
2. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.
Vizza E; Corrado G; De Angeli M; Carosi M; Mancini E; Baiocco E; Chiofalo B; Patrizi L; Zampa A; Piaggio G; Cicchillitti L
J Exp Clin Cancer Res; 2018 Jan; 37(1):16. PubMed ID: 29382392
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.
Benati M; Montagnana M; Danese E; Mazzon M; Paviati E; Garzon S; Laganà AS; Casarin J; Giudici S; Raffaelli R; Ghezzi F; Franchi M; Lippi G
Pathol Oncol Res; 2020 Oct; 26(4):2281-2289. PubMed ID: 32462419
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
5. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
Bakkum-Gamez JN; Wentzensen N; Maurer MJ; Hawthorne KM; Voss JS; Kroneman TN; Famuyide AO; Clayton AC; Halling KC; Kerr SE; Cliby WA; Dowdy SC; Kipp BR; Mariani A; Oberg AL; Podratz KC; Shridhar V; Sherman ME
Gynecol Oncol; 2015 Apr; 137(1):14-22. PubMed ID: 25677060
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.
Chang CC; Wang HC; Liao YP; Chen YC; Weng YC; Yu MH; Lai HC
J Gynecol Oncol; 2018 Jan; 29(1):e17. PubMed ID: 29185275
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
8. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
9. Biological markers with potential clinical value in endometrial cancer - review of the literature.
Taoussi N; Alghamdi A; Futyma K; Rechberger T
Ginekol Pol; 2017; 88(6):331-336. PubMed ID: 28727134
[TBL] [Abstract][Full Text] [Related]
10. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklinska W; Chyczewski L; Kulikowski M
Int J Cancer; 2010 Aug; 127(3):612-21. PubMed ID: 19960433
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer.
Cicchillitti L; Corrado G; Carosi M; Dabrowska ME; Loria R; Falcioni R; Cutillo G; Piaggio G; Vizza E
Oncotarget; 2017 Jan; 8(5):7935-7945. PubMed ID: 27974701
[TBL] [Abstract][Full Text] [Related]
12. A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction.
Lou X; Hou Y; Liang D; Peng L; Chen H; Ma S; Zhang L
Int J Mol Med; 2015 Jan; 35(1):72-80. PubMed ID: 25374065
[TBL] [Abstract][Full Text] [Related]
13. Aberrant MicroRNA Expression in Patients With Endometrial Cancer.
Montagnana M; Benati M; Danese E; Giudici S; Perfranceschi M; Ruzzenenete O; Salvagno GL; Bassi A; Gelati M; Paviati E; Guidi GC; Franchi M; Lippi G
Int J Gynecol Cancer; 2017 Mar; 27(3):459-466. PubMed ID: 28129244
[TBL] [Abstract][Full Text] [Related]
14. Quantitative DNA methylation analysis of selected genes in endometrial carcinogenesis.
Chen YC; Tsao CM; Kuo CC; Yu MH; Lin YW; Yang CY; Li HJ; Yan MD; Wang TJ; Chou YC; Su HY
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):572-9. PubMed ID: 26522113
[TBL] [Abstract][Full Text] [Related]
15. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
16. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of DNA content assessment in endometrial cancer.
Mauland KK; Wik E; Salvesen HB
Cytometry B Clin Cytom; 2014 May; 86(3):154-63. PubMed ID: 24532190
[TBL] [Abstract][Full Text] [Related]
18. High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome.
Li P; Yin H; Meng F; Liu S; Liu H; Ma R
Pathol Res Pract; 2018 May; 214(5):727-731. PubMed ID: 29526558
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
